Type I and Type III collagen expression in fibroblasts

Type I and Type III collagen expression in fibroblasts is a fundamental biological process responsible for the synthesis of the primary structural components of the extracellular matrix (ECM). Type I collagen (COL1A1/COL1A2) provides tensile strength to tissues like skin, bone, and tendons, while Type III collagen (COL3A1) is essential for the integrity of hollow organs and is highly expressed during the initial phases of wound healing (Source: UniProt, P02452, P02461). This process is tightly regulated by signaling pathways, most notably the Transforming Growth Factor-beta (TGF-beta)/SMAD pathway, which drives the activation of fibroblasts into myofibroblasts (Source: PubMed, PMID: 28232326). Pathological over-expression of these collagens leads to fibrosis, a condition characterized by excessive scarring and organ failure, seen in diseases such as systemic sclerosis and idiopathic pulmonary fibrosis (Source: NIH, StatPearls - Fibrosis). Conversely, reduced collagen production is a hallmark of skin aging and impaired wound healing. Pharmacological intervention involves either inhibiting collagen synthesis using drugs like Pirfenidone and Nintedanib for fibrotic conditions or stimulating production using agents like Retinoids for dermatological applications (Source: PubChem, CID 40632, CID 9809715).

Other names

Collagen synthesisFibroblast collagen productionExtracellular matrix depositionProcollagen expression

Modulation of the TGF-beta/SMAD signaling pathway, inhibition of pro-fibrotic cytokines, or activation of collagen gene transcription via nuclear receptors.